Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuhiro Koh

Showing results (41-50 of 150) with videos related to

Pageof 15
Sort By:
European Journal of Cancer (Oxford, England : 1990)|February 15, 2012
Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesotheliomaKyoichi Kaira, Masakuni Serizawa, Yasuhiro Koh, et al.
Journal of Medicinal Chemistry|January 4, 2011
Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluationArun K Ghosh, Bruno D Chapsal, Abigail Baldridge, et al.
Antimicrobial Agents and Chemotherapy|May 5, 2010
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitroYasushi Tojo, Yasuhiro Koh, Masayuki Amano, et al.
Antimicrobial Agents and Chemotherapy|October 29, 2008
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitroYasuhiro Koh, Debananda Das, Sofiya Leschenko, et al.
Internal Medicine (Tokyo, Japan)|November 26, 2023
Detection of the JAK2 V617F Mutation in Urinary Cell-free DNA in Patients with Myeloproliferative NeoplasmsHiroki Hosoi, Yoshikazu Hori, Katsuhiro Fukutsuka, et al.
Therapeutic Advances in Medical Oncology|January 29, 2024
Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L)Yuichi Ozawa, Yasuhiro Koh, Tetsunari Hase, et al.
BMC Cancer|February 8, 2020
Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapyNahomi Tokudome, Yasuhiro Koh, Hiroaki Akamatsu, et al.
Acute Medicine & Surgery|May 10, 2021
Comparison of Systemic Inflammatory Response Syndrome and quick Sequential Organ Failure Assessment scores in predicting bacteremia in the emergency departmentKatsuyuki Furuta, Hiroaki Akamatsu, Ryuichi Sada, et al.
Virchows Archiv : an International Journal of Pathology|January 22, 2011
MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinomaKyoichi Kaira, Haruyasu Murakami, Masakuni Serizawa, et al.
Internal Medicine (Tokyo, Japan)|April 7, 2011
Malignant pleural effusion from lung adenocarcinoma treated by gefitinibAkihito Kubo, Yasuhiro Koh, Tomoya Kawaguchi, et al.
Pageof 15

Showing results (41-50 of 150) with videos related to

Sort By:
Pageof 15
European Journal of Cancer (Oxford, England : 1990)|February 15, 2012
Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesotheliomaKyoichi Kaira, Masakuni Serizawa, Yasuhiro Koh, et al.
Journal of Medicinal Chemistry|January 4, 2011
Design and synthesis of potent HIV-1 protease inhibitors incorporating hexahydrofuropyranol-derived high affinity P(2) ligands: structure-activity studies and biological evaluationArun K Ghosh, Bruno D Chapsal, Abigail Baldridge, et al.
Antimicrobial Agents and Chemotherapy|May 5, 2010
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitroYasushi Tojo, Yasuhiro Koh, Masayuki Amano, et al.
Antimicrobial Agents and Chemotherapy|October 29, 2008
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitroYasuhiro Koh, Debananda Das, Sofiya Leschenko, et al.
Internal Medicine (Tokyo, Japan)|November 26, 2023
Detection of the JAK2 V617F Mutation in Urinary Cell-free DNA in Patients with Myeloproliferative NeoplasmsHiroki Hosoi, Yoshikazu Hori, Katsuhiro Fukutsuka, et al.
Therapeutic Advances in Medical Oncology|January 29, 2024
Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L)Yuichi Ozawa, Yasuhiro Koh, Tetsunari Hase, et al.
BMC Cancer|February 8, 2020
Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapyNahomi Tokudome, Yasuhiro Koh, Hiroaki Akamatsu, et al.
Acute Medicine & Surgery|May 10, 2021
Comparison of Systemic Inflammatory Response Syndrome and quick Sequential Organ Failure Assessment scores in predicting bacteremia in the emergency departmentKatsuyuki Furuta, Hiroaki Akamatsu, Ryuichi Sada, et al.
Virchows Archiv : an International Journal of Pathology|January 22, 2011
MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinomaKyoichi Kaira, Haruyasu Murakami, Masakuni Serizawa, et al.
Internal Medicine (Tokyo, Japan)|April 7, 2011
Malignant pleural effusion from lung adenocarcinoma treated by gefitinibAkihito Kubo, Yasuhiro Koh, Tomoya Kawaguchi, et al.
Pageof 15